الدكتور فيجاي جوبتا | جامعة حمد بن خليفة

الدكتور فيجاي جوبتا

باحث ما بعد الدكتوراه

البريد الإلكتروني

vgupta@hbku.edu.qa

الدكتور فيجاي جوبتا

باحث ما بعد الدكتوراه

الكيان

معهد قطر لبحوث الطب الحيوي

Divison

مركز بحوث الاضطرابات العصبية

السيرة الذاتية

Dr. Vijay Gupta received his Master’s degree in Microbiology from CCS University, Meerut, India and Ph.D. at the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, INDIA (2006). Dr. Gupta was awarded ASCB pre-doctoral travel award to attend ASCB annual meeting in 2005, Carl Storm International Diversity Fellowship to attend the Gordon Research Conference in University of New England, Maine, USA 2006 and later on Royal Society International Incoming Fellowship (2006) from the Royal Society, London, UK to perform research at The University of Bristol where he worked for fifteen months with the honorary title of Royal Society International Research fellow. He joined The Scripps Research Institute, La Jolla, USA on Target Characterization Fellowship funded by Cystic Fibrosis Foundation, USA as CF fellow for five years and then moved to University of California, San Diego as Assistant Project Scientist where he worked till June, 2017.

Dr. Gupta has multidisciplinary research experience in the fields of protein trafficking, cancer and human genetic diseases and has published more than fifteen publications including top-tier journals such as Nature Chemical biology, Developmental Cell, PNAS, JCS and Traffic. He is an invited member of Sigma Xi- Scientific Honor Society, elected 2013, invited member of Cell Stress Society International (CSSI), USA, peer review board member of JoVe and Dove press and has reviewed more than thirty manuscripts. One of the hobbies of Dr. Gupta is popular science writing for the general public, aimed at raising scientific awareness.

 

  • The aim of the current research project focuses on using a fusion protein engineered to include the FAb region of existing α-Syn antibodies. This single-chain-fragment-variable is designed to have increased BBB penetration by virtue of its smaller size and its conjugation with a carrier. It is envisaged that with enhanced penetration there will be superior brain targeting results compared to conventional α-syn antibodies.

  • Farquhar and Pradipta Ghosh. “GIV/Girdin activates Gαi and inhibits Gαs via the same motif”. PNAS. 2016 Sep 27;113(39):E5721-30.

  • Farquhar and Pradipta Ghosh, “CDK5 Activates Guanine Nucleotide Exchange Factor GIV/Girdin to Orchestrate Migration-Proliferation Dichotomy”. PNAS, 2015 Sep 1;112:E4874-83.

  • Farquhar,* and Pradipta Ghosh * “Activation of Gi at the Golgi by GIV/Girdin Imposes Finiteness in Arf1 Signaling”. Dev. Cell 33, 1–15, April 20, 2015.

  • J Proteome Res. 2014 13 (11), PP 4668-4675.

  • 2013 Jan; 9(1):12-4.

  • “Kinesin-1 (uKHC/KIF5B) is required for bidirectional motility of ER exit sites and efficient ER-to-Golgi transport” Traffic, Volume 9, Issue 11 , Pages 1850-66, (2008).